Adaptimmune Therapeutics PLC expected to post a loss of 25 cents a share - Earnings Preview

Adaptimmune Therapeutics

03/03/2023 08:32

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 6. 
    * The Abingdon Oxfordshire-based  company is expected to
report  a
191.1% increase in revenue to $4.125 million from $1.42 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Adaptimmune
Therapeutics
PLC is for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $5​, above​ its last closing price of $1.64.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.28       -0.24      -0.24     Met     0.7
 Jun. 30 2022  -0.28       -0.25      -0.28     Missed  -14.2
 Mar. 31 2022  -0.24       -0.22      -0.30     Missed  -36.8​
 Dec. 31 2021  0.26        0.14       -0.24     Missed  -271.4
 ​​Sep.        -0.26       -0.26      -0.30     Missed  -13.2
 30 2021                                                
 Jun. 30 2021  -0.24       -0.24      -0.24     Met     2​
 Mar. 31 2021  -0.25       -0.25      -0.24     Beat    4
 Dec. 31 2020  -0.23       -0.23      -0.24     Missed  -3.3
 This summary was machine generated March 3 at 08:31 GMT.  All
figures in US dollars  unless otherwise stated